CytoDyn Inc. (OTC: CYDY) Monoclonal antibody for treating HIV and Cancer. Potential FDA approval for HIV in 2019

January 3, 2019 admin CEO Interview, Healthcare, Spotlight Stocks Comments Off on CytoDyn Inc. (OTC: CYDY) Monoclonal antibody for treating HIV and Cancer. Potential FDA approval for HIV in 2019
Nader Pourhassan, Ph.D

 

 

 

Nader Pourhassan, Ph.D

 

 

 

 

 

 

 

 

CytoDyn Inc. (OTC: CYDY) CEO Interview with Nader Pourhassan, Ph.D, discussing CytoDyn’s PRO140 monoclonal antibody therapy for HIV and cancer.

The company is at a key inflection point, with potential FDA approval for PRO140 for treating HIV expected in 2019. 

Dr. Pourhassan explains the PRO140 technology, its numerous advantages over current HIV therapies on the market, market potential, as well as expanding PRO140’s indications for treating cancer. 

Investor Presentation

CytoDyn_Investor_Presentation
Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.




Related Articles

CEO Interview

CytoDyn, Inc. (OTC: CYDY) “Game Changer” HIV treatment nears commercialization (plus high-potential cancer drug pipeline)

May 10, 2019 admin CEO Interview, Healthcare Comments Off on CytoDyn, Inc. (OTC: CYDY) “Game Changer” HIV treatment nears commercialization (plus high-potential cancer drug pipeline)

            CytoDyn Inc. (OTC: CYDY) CEO Interview with Nader Pourhassan, Ph.D, providing an update on the company’s drug development pipeline targeting HIV and cancers, based on CytoDyn’s Leronlimab/PRO 140 platform. […]

Healthcare

FDA Grants Rolling Review for CytoDyn’s (OTC: CYDY) Planned BLA for Investigational HIV Therapy Leronlimab (PRO 140)

March 7, 2019 admin Healthcare, Newsmakers Comments Off on FDA Grants Rolling Review for CytoDyn’s (OTC: CYDY) Planned BLA for Investigational HIV Therapy Leronlimab (PRO 140)

VANCOUVER, Washington, March 04, 2019 — CytoDyn Inc. (otc.qb:CYDY), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the FDA has reviewed […]